Berlin is no longer well-known only for its amazing cultural landscape and clubbing locations. Today, the German capital is one of the top three European tech start-up cities. This is a major attraction for investors, big pharma companies, and high-class researchers from all over the world who come to settle in the HealthCapital region Berlin-Brandenburg. During BIO-Europe in November, it offers the opportunity to dive into a fast-growing life sciences ecosystem.
German infection specialist InflaRx (Jena) raised US$55m in a Series D financing co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC to finance its clinical programmes with its lead asset IFX-1.
https://european-biotechnology.com/wp-content/uploads/2024/04/Inflaryx.png5601920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-10-13 18:19:002017-10-13 18:19:00InflaRX raises US$55m in Series D round
Norwegian Targovax ASA (Oslo) has reported tremendous safety, immunogenicity, and one-year survival data, of in the modified cohort of the TG01 trial in resected pancreatic cancer patients.
Sanofi is investing €170m to expand its vaccine manufacturing site in Val de Reuil, France, which produces 900 million vaccine doses worldwide each year.
Britishresearchers have identified interleukin 36 (IL-36) as a druggable proinflammatory driver of psoriasis. Because of its very targeted effects of antibodies directed against the cytokine they want to start clinical tests in man.
German-Israeli Neurim Pharmaceuticals announced top line efficacy results of its insomnia drug PedPRM in children with autism spectrum disorders (ASD).
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-10-11 09:07:412017-10-11 09:07:41Neurim tables Phase III data of insomnia drug
French cancer drug encapsulation specialist Erytech Pharma SA wants to raise US$100m (€85m) in an IPO at NASDAQ and a subsequent private placement outside Northern America to finance pivotal trials of eryaspase in ALL and pancreatic cancer.
https://european-biotechnology.com/wp-content/uploads/2024/04/Erytech.png436843Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-10-10 06:18:382017-10-10 06:18:38Erytech Pharma set to raise US$100m in IPO and private placement
https://european-biotechnology.com/wp-content/uploads/2024/04/uniqure_Gene_therapy_NIH.jpg371495Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-10-09 06:06:322017-10-09 06:06:32uniQures AMT-130 receives FDA Orphan Drug Designation in Huntingtons disease
https://european-biotechnology.com/wp-content/uploads/2024/04/Microsart_Sartorius_PDW.PNG450800Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2017-10-08 00:00:002024-04-02 15:51:46Advanced system for touch-free membrane transfer
Exciting. Innovative. Berlin. A fast-growing ecosystem
Sponsored PublicationsBerlin is no longer well-known only for its amazing cultural landscape and clubbing locations. Today, the German capital is one of the top three European tech start-up cities. This is a major attraction for investors, big pharma companies, and high-class researchers from all over the world who come to settle in the HealthCapital region Berlin-Brandenburg. During BIO-Europe in November, it offers the opportunity to dive into a fast-growing life sciences ecosystem.
InflaRX raises US$55m in Series D round
Latest NewsGerman infection specialist InflaRx (Jena) raised US$55m in a Series D financing co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC to finance its clinical programmes with its lead asset IFX-1.
Lipotype performed lipid analysis
Sponsored PublicationsLipid analysis for early stages of drug discovery for Flagship VentureLabs with the aim to better understand molecular compositions of chondrisomes.
Targovax reports 100% one-year survival in pancreatic cancer trial
Latest NewsNorwegian Targovax ASA (Oslo) has reported tremendous safety, immunogenicity, and one-year survival data, of in the modified cohort of the TG01 trial in resected pancreatic cancer patients.
Sanofi invests €170m to expand flu jab facility
Latest NewsSanofi is investing €170m to expand its vaccine manufacturing site in Val de Reuil, France, which produces 900 million vaccine doses worldwide each year.
Researchers describe alternative psoriasis target
Latest NewsBritish researchers have identified interleukin 36 (IL-36) as a druggable proinflammatory driver of psoriasis. Because of its very targeted effects of antibodies directed against the cytokine they want to start clinical tests in man.
Neurim tables Phase III data of insomnia drug
Latest NewsGerman-Israeli Neurim Pharmaceuticals announced top line efficacy results of its insomnia drug PedPRM in children with autism spectrum disorders (ASD).
Erytech Pharma set to raise US$100m in IPO and private placement
Latest NewsFrench cancer drug encapsulation specialist Erytech Pharma SA wants to raise US$100m (€85m) in an IPO at NASDAQ and a subsequent private placement outside Northern America to finance pivotal trials of eryaspase in ALL and pancreatic cancer.
uniQures AMT-130 receives FDA Orphan Drug Designation in Huntingtons disease
Latest NewsAs first gene therapy ever, AMT-130 has been granted FDA Orphan Drug status in Huntingtons Disease.
Advanced system for touch-free membrane transfer
ProductsMicrosart ® @media Advanced System for Touch-free Membrane Transfer.